V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 180012941 | 180003296 | null | null | null | null | 2019-01-20 | NB HRNBL-1 MOD N7 CAV | null | null | NB HRNBL-1 ISOTRETINOIN | 100218966 |
| 180013089 | 180003299 | null | null | null | 2019-03-02 | 2019-03-28 | null | null | null | DINUTUXIMAB BETA | 100101985 |
| 180013132 | 180003301 | null | null | null | 2018-05-01 | 2018-05-24 | null | null | null | PACLITAXEL | 100829507 |
| 180013161 | 180003302 | null | null | null | null | 2018-11-26 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | 02 | null | LENALIDOMIDE + RITUXIMAB | 100544387 |
| 180013224 | 180003305 | null | null | null | 2021-05-15 | 2022-02-19 | null | null | null | CISPLATIN + GEMCITABINE | 101279217 |
| 180013322 | 180003307 | 1.64 | null | null | null | 2018-09-01 | BORTEZOMIB + THALIDOMIDE | null | null | LEAM | 100503947 |
| 180013380 | 180003309 | null | null | null | null | 2019-07-29 | Aldesleukin | 02 | null | LENVATINIB | 101206781 |
| 180000146 | 180003311 | null | null | null | null | 2021-12-17 | EDP + MITOTANE | null | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100641537 |
| 180009463 | 180003342 | null | null | null | 2020-05-30 | 2020-07-24 | PEMBROLIZUMAB | null | null | CYCLOPHOSPHAMIDE + VINCRISTINE | 100961749 |
| 180009619 | 180003343 | null | null | null | null | 2017-10-19 | null | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101680232 |
| 180012631 | 180003355 | null | null | null | 2020-01-19 | 2020-02-09 | NB HRNBL-1 ch14.18/CHO only (trial) | null | null | CISPLATIN + PACLITAXEL | 100235110 |
| 180000442 | 180003358 | null | null | null | null | 2020-09-17 | Cisplatin+Doxorubicin+Etoposide 28d | null | null | LENVATINIB | 101227627 |
| 180000098 | 180003363 | 0 | null | null | 2019-01-15 | 2019-01-15 | Enzalutamide | null | null | CISPLATIN + PEMETREXED | 101425257 |
| 180000208 | 180003366 | null | null | null | null | 2017-03-27 | CEOP | null | null | CAPECITABINE + MITOMYCIN | 101510937 |
| 180000408 | 180003374 | null | null | null | 2020-07-06 | 2020-07-08 | Temozolomide 200mg/m2 | null | null | PEMBROLIZUMAB | 100662834 |
| 180000707 | 180003379 | null | null | null | 2019-05-20 | 2019-07-18 | NB HRNBL-1 TVD | null | null | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 101844229 |
| 180000738 | 180003380 | null | null | null | 2019-05-28 | 2019-06-20 | Capecitabine + Mitomycin | null | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 101347758 |
| 180000768 | 180003381 | null | null | null | null | 2018-08-11 | IPILIMUMAB + NIVOLUMAB | null | null | NB HRNBL-1 ISOTRETINOIN | 100508215 |
| 180001158 | 180003387 | null | null | null | 2018-12-21 | 2018-12-22 | NIVOLUMAB | null | null | NOT MATCHED | 101524384 |
| 180001169 | 180003388 | null | null | null | 2019-12-06 | 2019-12-11 | Trial Unspecified | null | null | SELPERCATINIB | 100209111 |
| 180001219 | 180003389 | null | null | null | null | 2017-01-19 | BUSULFAN + MELPHALAN | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100973705 |
| 180001263 | 180003391 | null | null | null | 2019-07-25 | 2019-07-25 | NB Low/Interm risk guidelines Carbo/Etop | null | null | FLUOROURACIL + IRINOTECAN | 101455646 |
| 180001453 | 180003396 | null | null | null | null | 2019-12-27 | Irinotecan + Modified De Gramont | null | null | NB REL GD2CH14.18/CHO, IL-2 ISOTRET | 100251538 |
| 180001552 | 180003397 | null | null | null | 2017-10-23 | 2017-11-18 | null | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100810603 |
| 180001624 | 180003398 | null | null | null | null | 2019-03-18 | NB Rel CCLG guidelines Cyclo-Topotecan | null | null | CABOZANTINIB | 100784632 |
| 180001664 | 180003403 | null | null | null | 2022-01-09 | 2022-01-09 | Venetoclax | null | null | LENVATINIB | 101765930 |
| 180001777 | 180003405 | null | null | null | 2021-05-29 | 2021-05-29 | NB HRNBL-1 Isotretinoin | null | null | ETOPOSIDE | 100508713 |
| 180002031 | 180003410 | null | null | null | 2018-06-08 | 2019-05-11 | NB Rel CCLG guidelines Cyclo-Topotecan | null | null | FLUOROURACIL + IRINOTECAN | 101142828 |
| 180002212 | 180003416 | 1.81 | null | null | null | 2021-07-21 | Cisplatin + Etoposide (3 day) | null | null | BORTEZOMIB + THALIDOMIDE | 100351119 |
| 180002371 | 180003421 | null | null | null | null | 2020-08-06 | NB BEACON Dinutuximab, Cyclophosphamide and Topotecan | null | null | VANDETANIB | 101226723 |
| 180002532 | 180003422 | null | null | null | null | 2018-12-15 | NB Rel CCLG guidelines Cyclo-Topotecan | null | null | LENVATINIB | 101365730 |
| 180002642 | 180003423 | null | null | null | null | 2018-02-27 | Trial Unspecified | null | null | LIPOSOMAL DOXORUBICIN | 101173138 |
| 180003049 | 180003430 | null | null | null | 2019-11-19 | 2019-11-25 | CYCLOPHOSPHAMIDE | null | null | MITOTANE | 100308659 |
| 180003053 | 180003431 | null | null | null | 2021-10-03 | 2021-10-17 | NB HRNBL-1 BUMEL MAT | null | null | NOT MATCHED | 101792840 |
| 180003233 | 180003438 | null | null | null | null | 2019-11-08 | null | null | null | NOT MATCHED | 100041444 |
| 180003574 | 180003450 | null | null | null | 2018-02-11 | 2018-07-15 | LENVATINIB | null | null | SORAFENIB | 101706487 |
| 180003594 | 180003451 | null | null | null | null | 2017-05-03 | PERTUZUMAB + TRASTUZUMAB | null | null | NB HRNBL-1 ISOTRETINOIN | 101446736 |
| 180003693 | 180003457 | null | null | null | 2019-08-08 | 2020-02-21 | null | null | null | LENVATINIB | 101054188 |
| 180003840 | 180003460 | null | null | null | 2018-11-10 | 2019-12-20 | Paclitaxel 7 day | null | null | GEMCITABINE | 100441558 |
| 180003929 | 180003463 | null | null | null | null | 2018-09-19 | null | null | null | EW REL REECUR TOPOTECAN/CYCLOPHOSPHAMIDE | 101532194 |
| 180003947 | 180003465 | null | null | null | null | 2019-04-04 | Topotecan (intravenous) | null | null | LENVATINIB | 101532498 |
| 180004325 | 180003474 | null | null | null | 2019-12-08 | 2019-12-27 | CABOZANTINIB | null | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100248806 |
| 180004407 | 180003477 | 1.78 | null | null | 2014-10-21 | 2016-07-24 | MITOTANE | null | null | CARBOPLATIN + PACLITAXEL | 101520126 |
| 180004541 | 180003481 | null | null | null | null | 2019-12-14 | Trial Unspecified | null | null | NB BEACON DINUTUXIMAB + TEMOZOLOMIDE | 100403978 |
| 180004668 | 180003485 | null | null | null | 2020-03-17 | 2020-03-18 | LENVATINIB | null | null | MITOTANE | 100261581 |
| 180004777 | 180003486 | null | null | null | null | 2020-10-25 | CYCLO + DOXORUBICIN + VINCRISTINE | null | null | NB HRNBL-1 ISOTRETINOIN | 101052062 |
| 180005020 | 180003492 | null | null | null | 2022-01-18 | 2022-02-12 | null | null | null | VANDETANIB | 101661979 |
| 180005123 | 180003494 | null | null | null | 2017-11-09 | 2018-08-04 | CARBOPLATIN + PACLITAXEL + RT | null | null | NB HRNBL-1 ISOTRETINOIN | 100696295 |
| 180005234 | 180003499 | null | null | null | null | 2018-07-06 | NB 13 cis-RA (Isotretinoin) | null | null | LENVATINIB | 101213183 |
| 180005368 | 180003503 | null | null | null | null | 2020-02-01 | Trial Unspecified | null | null | NB BEACON TEMOZOLOMIDE AND TOPOTECAN | 101124008 |